Skip to main
RLAY
RLAY logo

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics Inc. is positioned for a promising trajectory due to its innovative drug candidate RLY-2608, which is expected to enhance the market for PI3Ka inhibitors through its best-in-class efficacy and improved tolerability compared to existing therapies like capivasertib. The positive clinical data surrounding RLY-2608 indicates a potential for rapid market uptake, especially given that capivasertib has already demonstrated significant sales growth, reportedly expanding the market to approximately $700 million. By addressing previously intractable targets in precision oncology and genetic disease through its advanced Dynamo platform, Relay Therapeutics is leveraging cutting-edge technology in its drug discovery process, reinforcing a positive outlook for its pipeline.

Bears say

Relay Therapeutics faces significant challenges due to a dramatic expected decrease in median progression-free survival (mPFS) from 24 months to just 5 months, which raises concerns about the efficacy of its treatments and is likely to impact patient outcomes negatively. Additionally, the commercial launch of inavolisib has fallen short of expectations attributed to safety liabilities related to its mechanism of action, particularly in patients with metabolic issues, which may hinder its market acceptance. This combination of disappointing clinical data and competitive pressures in the oncology market suggests a challenging path ahead for Relay Therapeutics, potentially leading to a negative outlook on its stock performance.

RLAY has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Buy based on their latest research and market trends.

According to 8 analysts, RLAY has a Buy consensus rating as of Nov 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.